CLAIMS

1- Use of a compound in the manufacture of a medicament~~Compound for use~~ for the treatment of a renal disease in a subject, wherein the compound is 4-halogeno-5-[4-(2,6-dichloro-benzenesulfonyl)-piperazin-1-yl]-benzofuran-2-carboxylic acid or a pharmaceutically salt thereof.

2- The ~~compound for~~ use according to claim 1, wherein the compound is 4-bromo-5-[4-(2,6-dichloro-benzenesulfonyl)-piperazin-1-yl]-benzofuran-2-carboxylic acid or a pharmaceutically salt thereof.

3- The ~~compound for~~ use according to claim 1, wherein the compound is 4-chloro-5-[4-(2,6-dichloro-benzenesulfonyl)-piperazin-1-yl]-benzofuran-2-carboxylic acid or a pharmaceutically salt thereof.

4- The ~~compound for~~ use according to any one of claims 1-3, wherein the renal disease is a chronic kidney disease (CKD).

5- The ~~compound for~~ use according to claim 4, wherein the CKD has a stage selecting from stage 1*, stage 1, stage 2 or stage 3 as defined in Table 1.

6- The ~~compound for~~ use according to claim 4, wherein the CKD has a stage selecting from stage 1, stage 2 or stage 3 as defined in Table 1.

7- The ~~compound for~~ use according to claim 4, wherein the CKD has a stage selecting from stage 1 or stage 2 as defined in Table 1.

8- The ~~compound for~~ use according to any one of claims 1-7, wherein the subject suffers from a hypertension, type 2 diabetes, type 1 diabetes, obesity, Non-Alcoholic Steatohepatitis (NASH), ageing, infectious glomerulonephritis, focal segmental glomerulosclerosis, IgA nephropathy, minimal change glomerulopathy, membranous nephropathy, renal vasculitis, urinary tract obstruction, genetic alterations, autoimmune diseases such as systemic lupus erythematosus (SLE), and drug- or toxin-induced nephropathy.

9- The ~~compound for~~ use according to any one of claims 1-7, wherein the subject has a renal fibrosis, especially a tubulointerstitial fibrosis.

10- The ~~compound for~~ use according to any one of claims 1-9, wherein the renal disease is selected from the group consisting of AIDS-associated nephropathy, ischemic nephropathy, tubulointerstitial nephropathy, hepatorenal syndrome, hydronephrosis, renal dysplasia, medullary cystic kidney disease, medullary sponge kidney, multicystic dysplastic kidney, podocytopathy, kidney papillary necrosis, nephritis including glomerulonephritis, hereditary nephritis, interstitial nephritis, pyelitis, nephrocalcinosis, nephrosclerosis, Alport's syndrome, Fabry's disease and renal sarcoidosis.

11- The ~~compound for~~ use according to any one of claims 1-9, wherein the renal disease is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, Sjogren's syndrome, Alagille syndrome, alpha 1-antitrypsin deficiency, and polycystic kidney disease.

12- The ~~compound for~~ use according to any one of claims 1-9, wherein the renal disease is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, Sjogren's syndrome, Alagille syndrome, alpha 1-antitrypsin deficiency, and polycystic kidney disease and the compound is 4-bromo-5-[4-(2,6-dichloro-benzenesulfonyl)-piperazin-1-yl]-benzofuran-2-carboxylic acid or a pharmaceutically salt thereof.

13- The ~~compound for~~ use according to any one of claims 1-9, wherein the renal disease is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, Sjogren's syndrome, Alagille syndrome, alpha 1-antitrypsin deficiency, and polycystic kidney disease and the compound is to be administered two or three times a day.

14- The ~~compound for~~ use according to any one of claims 1-13, wherein the compound is to be administered two or three times a day.

15- The ~~compound for~~ use according to any one of claims 1-13, wherein the compound is to be administered once a day.